Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The end of Qutenza sends NGX-1998 into the neuropathic pain fray

This article was originally published in Scrip

Executive Summary

Following the FDA's rejection of Qutenza (8% capsaicin patch) for the management of HIV-related pain, potential for the product in the future neuropathic pain market will remain limited to postherpetic neuralgia. NeurogesX will shift its focus to the development of NGX-1998 - a more user-friendly, liquid formulation of the drug. However, the shift towards an early pipeline product means that NeurogesX will have to face greater competition in the future neuropathic pain market as a number of agents are topical pipeline agents will provide fierce competition.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel